Gastric Cancer

Gastric cancer (also referred to as stomach cancer) typically develops in the mucus-producing cells that line the stomach.

  • What is Gastric Cancer?
  • Gastric Cancer & cannabinoids
  • Text references, literature discussion
    & clinical trials

What is Gastric Cancer?

Gastric Cancer (also referred to as stomach cancer) typically develops in the mucus-producing mucus-producing. cells that line the stomach.1


  • Fatigue
  • Being bloated after eating
  • Feel full after small portions of food
  • Persistent and severe heartburn
  • Severe and persistent difficulty with digesting
  • Unexplained and persistent nausea and vomiting
  • Unintended weight loss
  • Stomach pain

As other types of cancer, gastric cancer involves the growth of abnormal cells that contain mutations leading to uncontrollable cell division and growth. Similarly, it can spread and damage/destroy normal tissue.

It was observed that there is a link between a diet involving smoked and salted foods and gastric cancer. However, other risk factors such as smoking, family history, and long-term inflammation in the stomach may also play a role in the development of gastric cancer.1

  • Cannabinoids
  • Cannabinoid receptors
  • Endocannabinoids

  • THC

  • PPARα
  • CB1
  • GPR119
  • GPR55
  • TRPV1
  • GPR12

  • Anandamide
  • PEA
  • OEA
  • Terpenes
  • Strains
  • Enzymes
  • Metabolites



Synthesizing & Degrading Enzymes


The connection between Gastric Cancer
& cannabinoids

Grastric Cancer Xray Zoom Cellchange

Preclinical data proposes that the cannabinoid THC may be beneficial in the treatment of Gastric Cancer if cannabinoid receptors found in stomach cancer cells are targeted.2

CBD has been shown to exhibit anticancer activities against several cancers (e.g. stimulated cell death in gastric cancer), proposing that CBD may be used as a potential candidate in the treatment of gastric cancer.3

Note: If you have any further information relevant to the connection between Gastric Cancer and cannabinoids, or find any of the information inaccurate, outdated, or incomplete please contact us here.

Text references, literature discussion
& clinical trials

  • Text references
  • Literature discussion
  • Clinical trials

CB1, CB2, PPARα, TRPV1, GPR119 and GPR55 receptors were found to be expressed in the gastrointestinal tract. Endocannabinoids such as AEA, PEA, and OEA are biosynthesized in the gastrointestinal tract where they play a role in controlling several gastrointestinal processes through the binding of the endocannabinoid receptors (Borrelli & Izzo, 2009; Izzo, Muccioli, Ruggieri, & Schicho, 2015; Taschler, Hasenoehrl, Storr, & Schicho, 2016).

In rats, plant cannabinoids can also help in controlling the transit and motility of the gastrointestinal tract (Shook & Burks, 1989).

It was shown that G Protein-Coupled Receptor 12 plays a role in the modulation of metastasis process in cancer cells and CBD functions as an inverse agonist for this receptor (Brown, Laun, & Song, 2017).

It was shown that THC may help alleviate nausea and vomiting symptoms connected to gastric cancer (Gonzalez-Rosales & Walsh, 1997).

It was shown that AEA addition to the human gastric cancer cell line, HGC-27, stimulated cell proliferation at lower AEA concentrations, while cell proliferation was strongly inhibited through the induction of apoptosis at higher concentrations. A combination of high doses of AEA with the anticancer drug Paclitaxel exhibited a synergistic effect on cell growth, reducing gastric cancer cell viability (Miyato et al., 2009).

In both animal models and in vitro assays of gastric cancer, synthetic CB1 agonist WIN 55,212-2 was shown to exhibit antineoplastic and antiproliferative activity and has been suggested as an alternative to 5-Fluorouracil resistant gastric cancer cells (Oh et al., 2013; Park et al., 2011; X. Xian et al., 2016; X.-S. Xian et al., 2010; X.-S. Xian, Park, Choi, & Park, 2013).

In an in vitro study, it was demonstrated that cannabinoid receptor agonists such as anandamide (AEA), (R)-(+)-methanandamide (Meth-AEA), and CP 55,940 (CP) showed similar effects in decreasing cell viability of gastric cancer cells, highlighting the therapeutic potential of these receptor agonists in gastric cancer cells (Ortega et al., 2016).

Clinical trials

Want to know more about Gastric Cancer?

Then signup our FREE newsletter below